adalimumab   Click here for help

GtoPdb Ligand ID: 4860

Synonyms: D2E7 [6] | Humira®
Approved drug Immunopharmacology Ligand
adalimumab is an approved drug (FDA (2002), EMA (2003))
Compound class: Antibody
Comment: Adalimumab is an anti-TNFα monoclonal antibody with immunosuppresive activity [6]. It was the first fully human monoclonal antibody drug approved by the FDA.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

X-ray structures of the apo and TNFα-bound Fab fragment of adalimumab have been deposited to the RCSB Protein Data Bank (IDs 4NYL and 3WD5 respectively).

Biosimilars:
NameTrade nameCompanyClinical PhaseIndicationsReferences
adalimumab-atto; ABP 501 Amjevita; AmgevitaAmgenApproved (2016 FDA, 2017 EMA)As per reference agent[8]
adalimumab-adbm; BI 695501CyltezoBoehringer IngelheimApproved (2017 FDA and EMA)As per reference agent 
ZRC-3197ExemptiaCadila HealthcareApproved (2015 India)Rheumatoid arthritis[2,4]
adalimumab-bwwd; SB5HadlimaSamsung BioepisApproved (2019 FDA)As per originator reference agent 
adalimumab-aacf: MSB11022Idacio; KromeyaFresenius KabiApproved (2019 EMA, 2022 FDA)As per originator reference agent
BCD-057 BiocadPh 3 (NCT02762955)Plaque psoriasis 
adalimumab-adaz; GP2017Hyrimoz; Hefiya; HalimatozSandozApproved (2018 EMA and FDA)As per originator reference agent [7]
M923 Momenta PharmaceuticalsPh 3 (NCT02581345)Plaque psoriasis, rheumatoid arthritis  
adalimumab-fkjp; MYL-1401A; FKB327HulioMylan, Fujifilm Kyowa Kirin BiologicsApproved (2018 EMA, 2020 FDA)As per originator reference agent[9,12]
adalimumab-afzb; PF-06410293Abrilada; AmsparityPfizerApproved (2019 FDA, 2020 EMA)As per originator reference agent
adalimumab-aaty; CT-P17YuflymaCelltrion Healthcare Hungary KftApproved (2021 EMA, 2023 FDA)As per originator reference agent
adalimumab-aqvh; CHS-1420Yusimry Coherus BioSciencesApproved (2021 FDA)As per originator reference agent
IBI303 Innovent BiologicsPh 3 (NCT02893254)Active ankylosing spondylitis[1]
adalimumab-ryvk; AVT02Hukyndra; Libmyris; SimlandiAlvotech/DKSH/Stada Arzneimittel/TevaApproved (2021 EMA; 2024 FDA)As per originator reference agent. FDA approved this as an interchangeable biosimilar to Humira.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: adalimumab

Immunopharmacology Comments
Adalimumab is an anti-TNFα immunosuppresive drug.
Immunopharmacology Disease
Disease X-Refs Comment References
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
 Anti-TNFα monoclonal antibody therapy approved for RA
Ankylosing spondylitis Disease Ontology: DOID:7147
 Anti-TNFα monoclonal antibody therapy approved for ankylosing spondylitis.
Psoriasis Disease Ontology: DOID:8893
 Anti-TNFα monoclonal antibody therapy approved for psoriatic arthritis and plaque psoriasis.
Crohn's disease Disease Ontology: DOID:8778
OMIM: 266600
Orphanet: ORPHA206
 Anti-TNFα monoclonal antibody therapy approved for Crohn's disease.